HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

2 clinical trials · Condition

Record	Firm	Date
Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial (NCT07490990)	West China Hospital	2026-06-01
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen (NCT06123494)	Jiangsu HengRui Medicine Co., Ltd.	2024-01-09

Every clearance here is in the API, with alerts when new ones post.